Pavlo Kyrychenko

Suggest Changes
Learn More
BACKGROUND Patients treated with clopidogrel who have ≥1 loss of function alleles for CYP2C19 have an increased risk for adverse cardiovascular events. In 2010, the US Food and Drug Administration(More)
WHAT IS KNOWN AND OBJECTIVE There is conclusive evidence demonstrating that formulary restrictions are associated with reduced utilization and pharmacy spending of the restricted drugs. However,(More)
  • 1